PHILADELPHIA and LONDON, December 19 /PRNewswire/ --

- Award Winners were Chosen for Leading Innovation Through Technology in all Aspects of Scientific Literature and Patent Publications

Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced the winners of the 2007 Innovation Award, recognizing leadership in technology as it relates to all aspects of scientific literature and patent publications in India.

ALZENAU, Germany and CHERNOBYL, Ukraine, December 19 /PRNewswire/ -- NUKEM Technologies GmbH, Alzenau has handed over the Engineered Near Surface Disposal Facility at Chernobyl to the customer SSE Technocenter on 19 December 2007. By doing so, NUKEM as the first Western company, has successfully completed a plant for the treatment of radioactive waste on location Chernobyl up to the handover to the customer.

In the Engineered Near Surface Disposal Facility, short-life radioactive wastes accumulated in the nuclear power plant Chernobyl are stored following prior conditioning. The repository is situated 17 kilometres away from the power plant at the location VEKTOR within the 30-km zone.

SANTA CLARA, California, December 19 /PRNewswire/ --

- Marvell PXA 300 Application Processor Delivers Both Outstanding Multimedia and Optimal Business Applications Functionality

Marvell, (Nasdaq: MRVL), a leader in storage, communications, and consumer silicon solutions, and Samsung, announced the availability of the Samsung SPH-M4650 PDA phone with the Marvell(R) PXA 300 application processor running on Korea's LG Telecom network. The Marvell PXA 300 application processor enables high-end graphics, gaming, and multimedia capabilities for the Samsung SPH-M4650 as well as delivering optimal business applications while consuming ultra-low levels of power. The Samsung SPH-M4650 runs on the Microsoft Windows Mobile 6.0 Professional operating system.

AMSTERDAM, December 19 /PRNewswire/ --

- FDA Offers Special Protocol Assessment for Reviroc

Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

KING OF PRUSSIA, Pennsylvania, December 19 /PRNewswire/ --

- High levels of Type III von Willebrand Disease, a serious, hereditary bleeding disorder, found in region

A new study of twins indicates that the genetic foundation for the brain’s ability to recognize faces and places is much stronger than for other objects, such as words. The results, which appear in the December 19 issue of the Journal of Neuroscience, are some of the first evidence demonstrating the role of genetics in assigning these functions to specific regions of the brain.

“We are social animals who have specialized circuitry for faces and places,” says Arthur W. Toga, PhD, director of the Laboratory of NeuroImaging at UCLA School of Medicine. “Some people are better at recognizing faces and places, and this study provides evidence that it is partially determined by genetics.”

NEW YORK, December 19 /PRNewswire/ --

- Digital Media Vet Kaleil Isaza Tuzman to become Chairman and CEO and to Appoint new Slate of Directors

ROO Group (OTC Bulletin Board: RGRP) announced today that the company has entered into an Executive Management Agreement with KIT Capital pursuant to which it has agreed to appoint Kaleil Isaza Tuzman as Chairman and Chief Executive Officer commencing on January 9th, 2008. Mr. Isaza Tuzman will succeed Robert Petty, who will retain the office of Vice-Chairman of the Board of Directors and Founder.

GENEVA, Switzerland, December 19 /PRNewswire/ -- Merck KGaA announced today that it has entered into a worldwide licensing and collaboration agreement on behalf of its Merck Serono division with Idera Pharmaceuticals, Inc. of Cambridge, Massachusetts, USA (Nasdaq: IDRA) for the research, development, and commercialisation of Idera's Toll-like Receptor 9 (TLR9) agonists for the treatment of cancer.

SAN JOSE, California, December 19 /PRNewswire/ --

Micrel Inc., (Nasdaq: MCRL), an industry leader in analog, high bandwidth Communications and Ethernet IC solutions, today launched the MIC23250, the industry's smallest high efficient, dual 400mA 4 MHz PWM synchronous buck step-down converter housed in a tiny 2mm x 2mm, 10 lead MLF(R) package. This device is ideally suited for today's portable applications where high efficiency, low output ripple and small size are crucial. The MIC23250 utilizes a proprietary switching method called "Hyper Light Load(TM)" that achieves high efficiency, very low output ripple, and fast transient response while using very small output capacitors. The MIC23250 is available in volume with pricing starting at US$1.47 for 1K quantities.